Anteris Technologies Global (AVR) stock

Heart valves , market cap $626M

Heart valves for treating aortic stenosis

Market cap $626M

$5.99

+6.96%

As of 9:45 AM ET, delayed 15+ min · Live for Pro members

Why is AVR down?

Down 30% in 3 months, 25% under its 50-day average.

Down more than its industry: the 83 other stocks in it fell a median 1% over the same 3 months.

−2Dilution 169.9% more shares outstanding than a year ago

Tell me next time AVR moves

Free account, no card. An optional alert when AVR moves or its score changes.

Or see it live, free for 24 hours. No account.

4 more things pulling AVR's score down, for Pro members.

Quality Score

-4

Poor

In its industry

#81of 85

Medical Devices

Checks firing

1of 14

Trending down

From 52-week high

-45.8%

Below the 200-day

AVR's Quality Score was unchanged on Tue, Nov 3, at -4.

See AVR's 14 chart checksSee it live, free for 24 hours. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Key facts on AVR

Key facts on AVR
Holding it back	169.9% more shares than a year ago
Latest filing	8-K, Sep 23 Signed a material agreement

1 more reason behind AVR's -4, free with an account →4 more reasons behind AVR's -4, for Pro members.

AVR in the news

TodayWith its group.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

AVR catalysts

Coming up

After its last 4 reports it closed -1.4% on average, higher 1 of 4 times.

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on AVR and every other stock.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

AVR has 1 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on AVR, and all 14 on every stock.Get in free →

AVR RSI today: 40.3, below its 50-day and 200-day averages

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1440.3
Above 30, below 50.
MACD (12, 26, 9)Above signal
Crossed above its signal line 5 sessions ago.
50-day average$7.37
The price is 18.7% below it.
200-day average$7.40
The price is 19.1% below it.
50/200 crossDeath cross
The 50-day crossed below the 200-day on Nov 4.
ADX 1430.9
25 or more, with +DI below -DI.
Support$5.81
Swing low from Mar 9, 3.0% below the price.
Resistance$6.45
Swing high from Apr 14, 7.7% above the price.
52-week high$11.05
From Jul 6, 84.6% above the price.
52-week low$3.30
From Nov 21, 2025, 44.9% below the price.
Chart patternNone
No triangle, channel, or wedge in the last year.
Bollinger Bands (20, 2)Inside
The bands run from $5.56 to $6.79.
Volume1.5x
Against its 20-day average, for the time of day.

The deep dive on AVR

What it does and how it makes money4 findingsFor Pro members4 findings on what AVR does and how it makes money, for Pro members
Where it stands6 findingsFor Pro members6 findings on where AVR stands: its cash, debt, and share count, for Pro members
Who holds and trades it3 findingsInsiders bought $11.7M and sold $7.27M of shares on the open market in 90 days; the largest, 10% owner L1 Capital PTY LTD, bought $4.87M on Oct 5, 2026.Form 4, filed Oct 6, 2026

12 more findings on AVR, each with its source, for Pro membersGet in free →

How AVR ranks in Medical Devices

AVR is #81 of 85 by Quality Score.

How AVR ranks in Medical Devices
1	ATRCAtriCure	7/14	18
2	DXCMDexCom	4/14	18
3	HAEHaemonetics	7/14	17
	ATECAlphatec		Open for its score
	AXGNAxogen		Open for its score
	BAXBaxter International		Open for its score
81	AVRAnteris Technologies Global	1/14	-4

When does AVR report earnings, and what happens after?

Expected to report Thu Nov 12, after the close (in 8 days). Expected.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What AVR reported on Aug 11, 2026

The quarter

The figures are not read from the release yet.

“R&D expenses of $23.4 million were driven by the scaling of manufacturing and quality capabilities, including process development and validation activities and expanded headcount, together with PARADIGM trial related activities, including clinical costs associated with patient enrollment and the scaling of our field-based clinical team.”

The filing on EDGAR

Where the sales came from

AVR's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“The Company’s net operating cash outflows for the three months ended June 30, 2026 were $20.8 million, primarily attributable to clinical, regulatory and manufacturing requirements to support the PARADIGM Trial.”

From its results filing (SEC filing · Aug 11)

The numbers

Market value: $626M; today
Sales: $2.2M; down 9.6% on the year
Free cash flow: -$88.2M; last 12 months

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on AVR: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.Get in free →

+2.7%-2.5%-3.3%

Feb 26May 12Aug 11

Reported	When	Gap	Reaction	5 sessions
Aug 11, 2026After close	After close	-1.5%	-3.3%	+4.5%
May 12, 2026After close	After close	-3.7%	-2.5%	+14.9%
Feb 26, 2026After close	After close	-2.2%	+2.7%	-0.2%

AVR closed higher after 1 of its last 4 reports.

All 4 reports, and AVR's Quality Score going into each

Everyone reporting earnings next week

AVR sales and profit by year

Sales and profit by year

Sales fell in 2025, to $1.9M. It lost money in both years.

AVR share count over time

Shares: 2.7 times the count a year ago (to Jun 30).

Shares of AVR outstanding, as filed
Shares outstanding	As of
97.5M	Aug 10, 2026
97.3M	May 11, 2026
97.2M	Feb 25, 2026
41.2M	Nov 12, 2025

Offerings, shelves, and splits of AVR, from its filings
From its filings	Filed
Set up an at-the-market program for up to $250M of shares, about 40% of its market value	May 22, 2026
Raised $200M in a sale of shares, about 32% of its market value	Jan 22, 2026

Insiders trading AVR

AVR insider trades

2 insiders bought $11.8M across 6 filings, and one insider sold $25.2M across 13 filings, in the last 6 months. The newest:

BuyL1 Capital PTY LTD$2M10% ownerat $7.18 on Oct 6, filed Oct 8

BuyL1 Capital PTY LTD10% owner$2Mat $7.18 on Oct 6, filed Oct 8

All 19 insider filings on AVR from the last six months, for Pro members.Get in free →

All AVR insider trades

AVR's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Wayne PatersonChief Executive Officer
Matthew McDonnellChief Financial Officer
David St DenisChief Operating Officer
Susan Elizabeth KnightDirector · 1 trade
David B. RobertsDirector
Gregory S. MossDirector
John D. SeabergDirector

See insider trades by person

About Anteris Technologies Global

Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.

174 employeesEagan, MNanteristech.com

What Anteris Technologies Global says it competes with

“We compete in the cardiovascular device market, and in particular the TAVR market.”

From its annual report, SEC filing · Feb 26, 2026

2 more sentences, what it says it does, and its sales by region, for Pro membersGet in free →

AVR's score card

Anteris Technologies Global (AVR): Quality Score -4, Poor, #81 of 85 in Medical Devices, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would turn AVR's score around: 9 things
4 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayOct 8L1 Capital PTY LTD bought AVR$2M at $7.18, filed Oct 8

Alerts are optional.

See AVR's 14 chart checks

See it live, free for 24 hours. No account. No card. Then keep going with a free account.

Straight Answers

As of Nov 4, 2026: AVR's Quality Score is -4 (Poor), #81 of 85 in Medical Devices. Insiders bought $11.8M and sold $25.2M in the last 6 months (Form 4).

Is AVR a good stock to buy? What its Quality Score says

AVR scores -4 today, which Breakaway calls Poor. It is #81 of 85 in Medical Devices by Quality Score, with 1 of 14 chart checks firing. Down 30% in 3 months, 25% under its 50-⁠day average. Shares: 2.7 times the count a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is AVR's Quality Score?

AVR scores -4 today, which Breakaway calls Poor (below zero). That is #81 of 85 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind AVR's -4.

Are insiders buying AVR?

2 insiders bought $11.8M across 6 filings, and one insider sold $25.2M across 13 filings, in the last 6 months. The newest is L1 Capital PTY LTD, 10% owner, who bought $2M on Oct 6. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.